Please assess the completion status of the following clinical trial:

Trial Title: Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Newly diagnosed solid tumor or lymphoma with histological verification~2. Age 1 - 21 years at time of diagnosis~3. Karnofsky/Lanksy performance score of ≥ 50~4. Able to tolerate enteral medication administration~5. Planned chemotherapeutic regimen for a patient must meet all of the following criteria:~   * A known myelosuppressive regimen which includes at least two of the following agents: actinomycin, carboplatin, cisplatin, cyclophosphamide, daunorubicin, doxorubicin, etoposide, ifosfamide, topotecan~  * At least four consecutive cycles~  * Cycle length is either 14 or 21 days~  * Regimen must either alternate myelosuppressive chemotherapeutic agents in an X-Y-X-Y format, such that the same chemotherapy is given every other cycle (e.g. vincristine/doxorubicin/cyclophosphamide │ ifosfamide/etoposide), or repeat the same chemotherapeutic agents each cycle in an X-X-X-X format (e.g. repeated cycles of cisplatin/etoposide/bleomycin). Courses eligible for this trial may occur at any time during treatment provided that they are consecutive and follow the one of the described patterns. Non-myelosuppressive anti-neoplastic treatments will not be considered for the purposes of determining eligibility. Questions regarding whether or not a patient's chemotherapy plan meets inclusion criteria will be decided by the Study Chair.~6. Informed consent or parental permission and assent obtained prior to trial-related activities~7. Able and willing to comply with all study related procedures~8. Women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately~Exclusion Criteria~1. Known allergy to soy or any soy-based food or supplement~2. Unable or unwilling to discontinue consuming prohibited soy-based food or supplements while participating in this study~3. Pre-existing neutropenia or neutrophil qualitative or quantitative disorder~4. Pre-existing cytopenia or bone marrow failure syndrome~5. History of gastric or duodenal ulcers or hyperacidity syndromes~6. History of Human Immunodeficiency Virus (HIV)~7. Has an active infection requiring systemic therapy~8. Planned treatment does not include myelosuppressive chemotherapy~9. Enrolled on a therapeutic or supportive care clinical trial within the last 30 days~10. Current acute or chronic leukemia diagnosis~11. Requires medication dosing via an enteral feeding tube that terminates in the duodenum or jejunum. (Enteral feeding tubes that terminate in the stomach are acceptable for study medication delivery.)~12. Pregnant or breastfeeding woman~13. Incarceration~14. Secondary malignancy, i.e. the cancer for which the patient is presently or will be receiving treatment may not be a malignancy related to prior cancer therapy~15. Any condition which might be worsened by estrogen, such as breast cancer, uterine cancer, ovarian cancer, endometriosis or uterine fibroids~16. Any condition, in the investigator's opinion, that would compromise patient safety or study outcomes~17. Anyone who, in the investigator's discretion, would be unwilling or unable to comply with study procedures

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Genistein followed by Placebo (Type: EXPERIMENTAL): Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
- Arm B: Placebo followed by Genistein (Type: EXPERIMENTAL): Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4

Based on this trial design, predict the completion outcome and termination type (if applicable).